Use of corticosteroids in nonsevere community acquired pneumonia a propensity score matching study
Abstract
Community acquired pneumonia (CAP) is a major cause of morbidity and mortality. Although corticosteroids have shown benefits in severe CAP, their usefulness in non severe cases remains uncertain. This study assessed the association between systemic corticosteroids and 30-day mortality in adults hospitalized with non severe CAP. A multicenter retrospective cohort was conducted including adults hospitalized with non severe CAP between 2010 and 2020 in Colombia. Patients whose index episode was nosocomial pneumonia, as well as those with immunosuppression or connective tissue disease and those requiring vasopressors or mechanical ventilation, were excluded. Propensity score matching (1:1) was applied, and survival was analyzed using Kaplan Meier curves, including evaluations by corticosteroid type, dose and duration. A total of 2821 patients were included, with an overall 30-day mortality of 7.6%. Of these, 507 patients (18.0%) received corticosteroids, with a mortality rate of 10.4%, whereas the remaining 2314 patients who did not receive corticosteroids had a mortality rate of 7.0%. The propensity score-matched cohort included 448 patients (224 in each group). In the matched analysis, 30-day mortality was 14.3% among patients who received corticosteroids compared with 10.7% among those who did not. Before matching, patients treated with corticosteroids were older and had a higher burden of respiratory symptoms and comorbidities. After matching, baseline characteristics were well balanced between groups. After propensity score matching, no significant association was observed between corticosteroid use and 30-day mortality (average treatment effect on the treated [ATET] 0.031, 95% CI − 0.040 to 0.102; p = 0.389). The ATET estimates the absolute risk difference; an ATET of 0.031 corresponds to an absolute difference of 3.1 percentage points in 30-day mortality. Additionally, no significant differences in survival were found according to corticosteroid type, dose, or treatment duration. In adults with non-severe CAP, the use of systemic corticosteroids did not demonstrate a statistically significant difference in 30-day mortality.
Related
- Clinical outcomes of empirical antibiotic strategies in community-acquired pneumonia-associated sepsis: a propensity score-matched cohort study
- Beyond Digoxin Toxicity: A Fatal Case of BRASH Syndrome Triggered by Community-Acquired Pneumonia
- High Mortality in Adults With Community-Acquired Pneumonia Admitted to Hospitals in South Africa Before and During the COVID-19 Pandemic, Stratified by HIV Serostatus and Viral Load: Data From a Prospective Cohort Study (2019–2021)
- Community-acquired Acinetobacter baumannii pneumonia in Southern Vietnam : A retrospective cohort study
- Toward precision host-directed immunomodulation in community-acquired pneumonia: a proposed endotype–target–natural-product framework and a roadmap for validation in human lung organoids
BibTeX
@article{puentes2026corticosteroids,
title = {{Use of corticosteroids in nonsevere community acquired pneumonia a propensity score matching study}},
author = {Juan Sebastian Hernández Puentes and Alirio Rodrigo Bastidas Goyes and Laura F. Sánchez and Eduardo Andres Tuta Quintero and Juan Diego Castro Córdoba and Lina María López Nuñez and Laura F. Alzate and Sarah C. Bayona and Yuliana V. Rincón and Alejandra Charry and Gabriela Salcedo and Nicole Tovar and Luisa Fernánda Parra and Luisa Fernánda Martínez and David Castro and Ingrid S. Sanchez},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73712-3},
url = {https://www.nature.com/articles/s41598-026-73712-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Use of corticosteroids in nonsevere community acquired pneumonia a propensity score matching study
AU - Juan Sebastian Hernández Puentes
AU - Alirio Rodrigo Bastidas Goyes
AU - Laura F. Sánchez
AU - Eduardo Andres Tuta Quintero
AU - Juan Diego Castro Córdoba
AU - Lina María López Nuñez
AU - Laura F. Alzate
AU - Sarah C. Bayona
AU - Yuliana V. Rincón
AU - Alejandra Charry
AU - Gabriela Salcedo
AU - Nicole Tovar
AU - Luisa Fernánda Parra
AU - Luisa Fernánda Martínez
AU - David Castro
AU - Ingrid S. Sanchez
PY - 2026
DA - 2026/10/16
JO - Scientific Reports
DO - 10.1038/s41598-026-73712-3
UR - https://www.nature.com/articles/s41598-026-73712-3
AB - Community acquired pneumonia (CAP) is a major cause of morbidity and mortality. Although corticosteroids have shown benefits in severe CAP, their usefulness in non severe cases remains uncertain. This study assessed the association between systemic corticosteroids and 30-day mortality in adults hospitalized with non severe CAP. A multicenter retrospective cohort was conducted including adults hospitalized with non severe CAP between 2010 and 2020 in Colombia. Patients whose index episode was nosocomial pneumonia, as well as those with immunosuppression or connective tissue disease and those requiring vasopressors or mechanical ventilation, were excluded. Propensity score matching (1:1) was applied, and survival was analyzed using Kaplan Meier curves, including evaluations by corticosteroid type, dose and duration. A total of 2821 patients were included, with an overall 30-day mortality of 7.6%. Of these, 507 patients (18.0%) received corticosteroids, with a mortality rate of 10.4%, whereas the remaining 2314 patients who did not receive corticosteroids had a mortality rate of 7.0%. The propensity score-matched cohort included 448 patients (224 in each group). In the matched analysis, 30-day mortality was 14.3% among patients who received corticosteroids compared with 10.7% among those who did not. Before matching, patients treated with corticosteroids were older and had a higher burden of respiratory symptoms and comorbidities. After matching, baseline characteristics were well balanced between groups. After propensity score matching, no significant association was observed between corticosteroid use and 30-day mortality (average treatment effect on the treated [ATET] 0.031, 95% CI − 0.040 to 0.102; p = 0.389). The ATET estimates the absolute risk difference; an ATET of 0.031 corresponds to an absolute difference of 3.1 percentage points in 30-day mortality. Additionally, no significant differences in survival were found according to corticosteroid type, dose, or treatment duration. In adults with non-severe CAP, the use of systemic corticosteroids did not demonstrate a statistically significant difference in 30-day mortality.
SN - 2045-2322
ER -